Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

NAVEOS® Reports This Is a Time of Great Opportunity and Great Threat for the 340B Drug Pricing Program
  • USA - English


News provided by

NAVEOS

Dec 15, 2015, 04:00 ET

Share this article

Share toX

Share this article

Share toX


The number of hospitals that would be hurt by the Proposed Guidance is staggering.” ~ Ted Slafsky

Post this

Sterling, VA (PRWEB) December 15, 2015 -- NAVEOS® reports that Medicaid expansion has opened up eligibility for the 340B Drug Pricing Program to many hospitals that did not previously qualify because their Medicare Disproportionate Share Percentage (DPP) was below the 340B Program threshold. The size of a hospital’s Medicaid population is the key component of the DPP. NAVEOS® states that the size of the hospital's Medicaid population is the key component of the DPP. To take advantage of the Affordable Care Act, also known as “Obamacare”, 30 States (including District of Columbia) have already expanded Medicaid eligibility to 138% of the Federal Poverty Level (“FPL”) or are considering an alternative to traditional Medicaid expansion (1). This has expanded the Medicaid population in the country by roughly 13 million people, or a 21% increase from pre-ACA levels.

NAVEOS® asserts Medicaid expansion not only benefits hospitals in States that have expanded Medicaid, but also many that have not yet taken that step by providing services to Medicaid members from geographically adjacent States that have expanded Medicaid.

In addition, NAVEOS®’ analysis show that the growing Medicaid population may offer a near-term opportunity for those hospitals that had previously qualified for the 340B Program, but lost eligibility as their disproportionate patient percentage (“DPP”) fell below the qualification threshold due to a decrease in their Supplemental Security Income (SSI) ratio or a reduction in their Medicaid utilization. These facilities may once again qualify and gain access to the 340B Program savings, which often amount to 15-20% of the annual Outpatient Pharmaceutical cost. These savings, NAVEOS® states, are the keystone of the Program’s goal to help offset the cost of serving the neediest population, by allowing them to stretch scarce Federal dollars to fund outpatient drugs and other services.

NAVEOS® urges hospitals to examine their Medicaid population carefully to determine if they either qualify for the 340B Program for the first time, or if they may qualify to return to the Program if they have fallen below the required threshold. Certain categories of hospitals, such as Sole Community Hospitals and Rural Referral Centers, are allowed into the 340B Program by meeting a lower DPP threshold than those categorized by the Program as Disproportionate Share (“DSH”) Hospitals. NAVEOS® believes that the expanded Medicaid population may allow Rural Referral Centers and Sole Community Hospitals to meet the higher threshold and attain DSH hospital status for the 340B Program. In doing so, this will provide protection from some proposed cuts to the Program and provide access to Orphan Drugs which will be described later.

However, a recent analysis conducted by NAVEOS® shows that the recently released Proposed Guidance, as well as several lawsuits filed by the pharmaceutical industry, have created obstacles for hospitals and threaten to reduce the patient benefits associated within the 340B Program. NAVEOS® advises Hospitals to study the Proposed Guidance and other 340B Program related actions to determine the negative impact on them as well as their patients. They should educate their elected representatives on the impact of the proposed legislation in an attempt to mitigate their losses as well as the long-term impact on the 340B Program.

NAVEOS® encourages hospitals to focus on these key issues:

• New policies for record keeping that are far beyond what has been standard in the past and which may not be feasible for many facilities to meet.
• Increased program audits with numbers, breadth and depth far exceeding past established practices.
• Removal of 340B coverage of “Orphan Drugs” for rural and small hospitals. The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition. Orphan Drugs are critical to the health and well-being of patients who need them and are so costly that it will be difficult, and perhaps impossible, for many facilities to provide these drugs without the 340B coverage.

In the Oct. 29, 2015 HFMA Business News, Rich Daly, HFMA Senior Writer/Editor quotes Ted Slafsky, President and CEO of 340B Health, who said “about one-third of its 1,100 hospital members have reported they would leave the Program if the Proposed Rule changes are finalized.”

Click on the following articles recommended by NAVEOS® for more information about this topic:

Federal Judge’s Ruling Imperils 340B Hospitals
HHS Rule Agenda Includes 340B, FDA Regulations
OIG Report Examines Potential Scenarios for Restructuring 340B Program

(1) https://www.statereforum.org/Medicaid-Expansion-Decisions-Map?gclid=Cj0KEQjw27etBRDA3-ux4p3c58EBEiQAkJzTANiy471hd5Hwfq8XPh1q2Iq_zkUY8jo8EjkRxZ8LZj0aAglt8P8HAQ

About NAVEOS®

NAVEOS® is a national healthcare data analytics firm headquartered in Virginia focused on maximizing governmental healthcare program reimbursements for hospitals. With its patented technology and domain expertise and processes, NAVEOS® analyzes patient populations to ensure that its hospital clients receive 100% of the governmental reimbursements to which they are entitled. Questions can be directed to NAVEOS® at [email protected] or (888)550-2708.

Robert Gricius, NAVEOS, http://www.NaveosData.com, +1 571-665-5080, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.